vs
Side-by-side financial comparison of Intellia Therapeutics, Inc. (NTLA) and SYPRIS SOLUTIONS INC (SYPR). Click either name above to swap in a different company.
SYPRIS SOLUTIONS INC is the larger business by last-quarter revenue ($30.3M vs $23.0M, roughly 1.3× Intellia Therapeutics, Inc.). SYPRIS SOLUTIONS INC runs the higher net margin — -12.9% vs -416.2%, a 403.3% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -9.5%). SYPRIS SOLUTIONS INC produced more free cash flow last quarter ($-1.5M vs $-69.4M). Over the past eight quarters, SYPRIS SOLUTIONS INC's revenue compounded faster (-7.7% CAGR vs -10.8%).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
Sypris Solutions Inc. is a U.S.-headquartered provider of highly engineered components and specialized technical services, primarily serving aerospace, defense, automotive and commercial industrial markets. It delivers custom manufacturing, performance testing, and value-added engineering support for mission-critical systems and parts for global enterprise clients.
NTLA vs SYPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $30.3M |
| Net Profit | $-95.8M | $-3.9M |
| Gross Margin | — | 4.6% |
| Operating Margin | -428.9% | -10.9% |
| Net Margin | -416.2% | -12.9% |
| Revenue YoY | 78.8% | -9.5% |
| Net Profit YoY | 25.7% | -2992.6% |
| EPS (diluted) | $-0.81 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | $30.3M | ||
| Q3 25 | $13.8M | $28.7M | ||
| Q2 25 | $14.2M | $31.4M | ||
| Q1 25 | $16.6M | $29.5M | ||
| Q4 24 | $12.9M | $33.4M | ||
| Q3 24 | $9.1M | $35.7M | ||
| Q2 24 | $7.0M | $35.5M | ||
| Q1 24 | $28.9M | $35.6M |
| Q4 25 | $-95.8M | $-3.9M | ||
| Q3 25 | $-101.3M | $517.0K | ||
| Q2 25 | $-101.3M | $-2.1M | ||
| Q1 25 | $-114.3M | $-899.0K | ||
| Q4 24 | $-128.9M | $135.0K | ||
| Q3 24 | $-135.7M | $390.0K | ||
| Q2 24 | $-147.0M | $16.0K | ||
| Q1 24 | $-107.4M | $-2.2M |
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 7.2% | ||
| Q2 25 | — | 8.2% | ||
| Q1 25 | — | 11.4% | ||
| Q4 24 | — | 16.1% | ||
| Q3 24 | — | 16.8% | ||
| Q2 24 | — | 15.9% | ||
| Q1 24 | — | 8.1% |
| Q4 25 | -428.9% | -10.9% | ||
| Q3 25 | -808.9% | -6.1% | ||
| Q2 25 | -772.2% | -4.6% | ||
| Q1 25 | -726.6% | -0.4% | ||
| Q4 24 | -1059.9% | 3.9% | ||
| Q3 24 | -1589.0% | 4.8% | ||
| Q2 24 | -1998.6% | 3.6% | ||
| Q1 24 | -394.0% | -3.9% |
| Q4 25 | -416.2% | -12.9% | ||
| Q3 25 | -735.2% | 1.8% | ||
| Q2 25 | -710.8% | -6.5% | ||
| Q1 25 | -687.6% | -3.0% | ||
| Q4 24 | -1001.2% | 0.4% | ||
| Q3 24 | -1489.5% | 1.1% | ||
| Q2 24 | -2112.6% | 0.0% | ||
| Q1 24 | -371.3% | -6.2% |
| Q4 25 | $-0.81 | $-0.17 | ||
| Q3 25 | $-0.92 | $0.02 | ||
| Q2 25 | $-0.98 | $-0.09 | ||
| Q1 25 | $-1.10 | $-0.04 | ||
| Q4 24 | $-1.27 | $0.00 | ||
| Q3 24 | $-1.34 | $0.02 | ||
| Q2 24 | $-1.52 | $0.00 | ||
| Q1 24 | $-1.12 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $449.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $671.4M | $17.8M |
| Total Assets | $842.1M | $107.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $449.9M | — | ||
| Q3 25 | $511.0M | — | ||
| Q2 25 | $459.7M | — | ||
| Q1 25 | $503.7M | — | ||
| Q4 24 | $601.5M | — | ||
| Q3 24 | $658.1M | — | ||
| Q2 24 | $691.1M | — | ||
| Q1 24 | $791.3M | — |
| Q4 25 | $671.4M | $17.8M | ||
| Q3 25 | $748.4M | $20.0M | ||
| Q2 25 | $715.3M | $18.7M | ||
| Q1 25 | $779.9M | $19.0M | ||
| Q4 24 | $872.0M | $19.6M | ||
| Q3 24 | $962.6M | $18.2M | ||
| Q2 24 | $971.1M | $19.0M | ||
| Q1 24 | $1.0B | $20.8M |
| Q4 25 | $842.1M | $107.8M | ||
| Q3 25 | $925.3M | $112.5M | ||
| Q2 25 | $898.9M | $105.8M | ||
| Q1 25 | $986.2M | $110.2M | ||
| Q4 24 | $1.2B | $119.4M | ||
| Q3 24 | $1.2B | $121.6M | ||
| Q2 24 | $1.2B | $124.2M | ||
| Q1 24 | $1.3B | $129.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-69.3M | $-1.1M |
| Free Cash FlowOCF − Capex | $-69.4M | $-1.5M |
| FCF MarginFCF / Revenue | -301.6% | -5.0% |
| Capex IntensityCapex / Revenue | 0.5% | 1.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-395.9M | $-6.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-69.3M | $-1.1M | ||
| Q3 25 | $-76.9M | $-178.0K | ||
| Q2 25 | $-99.6M | $1.1M | ||
| Q1 25 | $-148.9M | $-5.5M | ||
| Q4 24 | $-85.2M | $2.3M | ||
| Q3 24 | $-84.8M | $-4.8M | ||
| Q2 24 | $-58.2M | $6.2M | ||
| Q1 24 | $-120.7M | $-1.7M |
| Q4 25 | $-69.4M | $-1.5M | ||
| Q3 25 | $-76.9M | $-390.0K | ||
| Q2 25 | $-99.9M | $941.0K | ||
| Q1 25 | $-149.7M | $-5.5M | ||
| Q4 24 | $-86.2M | $1.9M | ||
| Q3 24 | $-86.1M | $-4.9M | ||
| Q2 24 | $-59.2M | $6.0M | ||
| Q1 24 | $-123.2M | $-2.0M |
| Q4 25 | -301.6% | -5.0% | ||
| Q3 25 | -558.2% | -1.4% | ||
| Q2 25 | -701.0% | 3.0% | ||
| Q1 25 | -900.1% | -18.8% | ||
| Q4 24 | -669.4% | 5.7% | ||
| Q3 24 | -945.2% | -13.8% | ||
| Q2 24 | -850.9% | 16.8% | ||
| Q1 24 | -425.7% | -5.7% |
| Q4 25 | 0.5% | 1.3% | ||
| Q3 25 | 0.2% | 0.7% | ||
| Q2 25 | 1.7% | 0.5% | ||
| Q1 25 | 4.4% | 0.0% | ||
| Q4 24 | 7.6% | 1.2% | ||
| Q3 24 | 14.0% | 0.4% | ||
| Q2 24 | 14.5% | 0.5% | ||
| Q1 24 | 8.7% | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 17.13× | ||
| Q3 24 | — | -12.21× | ||
| Q2 24 | — | 385.25× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
SYPR
| Sypris Electronics | $17.7M | 59% |
| Transferred At Point In Time | $12.5M | 41% |
